CLINICAL TRIALS PROFILE FOR QUAZEPAM
✉ Email this page to a colleague
All Clinical Trials for QUAZEPAM
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03708341 ↗ | Exogenous Melatonin in Intensive Care Unit Chronodisruption | Unknown status | Saint-Joseph University | Phase 3 | 2018-11-15 | To this day, a small number of studies have evaluated the effect of melatonin on the modifications of the characteristics of sleep in critical care units, with mostly a small studied population. However, no study has been realized on a large population, nor has it evaluated the association between genetic factors and response to treatment (melatonin), hence the originality of our study. In our study we hypothesized that systematic melatonin usage in ICU can ameliorate the total sleep time and the fragmentation index and can decrease the confusion related to sleep deprivation. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for QUAZEPAM
Condition Name
Clinical Trial Locations for QUAZEPAM
Clinical Trial Progress for QUAZEPAM
Clinical Trial Phase
Clinical Trial Sponsors for QUAZEPAM
Sponsor Name